Dosimetry of chimeric TNT in lung tumor patients

RADIOCHEMISTRY, RADIOPHARMACEUTICALS AND NUCLEAR MEDICINE

Dosimetry of chimeric TNT in lung tumor patients

CHEN Yangchun，

CHEN Shaoliang，

JU Dianwen，

SHI Hongcheng，

YAO Zhifeng

Nuclear Science and Techniques

Vol.18, No.4

pp.227-231

Published in print 20 Aug 2007

DOI：10.1016/S1001-8042(07)60051-7

CLC：R817.5,R734.2

49000

The purpose of this study was to assess the absorbed dose of tumor and main critical organs in ¹³¹I labeled chimeric tumor necrotic treatment (chTNT). In 9 patients, a single intravenous dose of (29.6±3.7) MBq/kg was administered. Blood samples were drawn at different time intervals, and urine was collected for up to one week. Tissue distribution of ¹³¹I –chTNT was followed for up to one week by gamma camera imaging. Absorbed doses to the whole body and to normal organs were computed according to the MIRD scheme using Mirdose-3 software. S-factors for lung tumors were estimated by comparison with lungs of similar mass and position in the body. It was found that mean serum disappearance half time values for ¹³¹I-chTNT were (4.93±9.36) h and (61.7±21.2) h for α, β respectively, while that for whole body was(99±10) h. Mean urine biological clearance half time value was (90±10) h. The absorbed dose to tumor was (8.28±2.65) Gy, and the tumor-to-nontumor dose ratio was 3.95±1.55. And the mean effective dose to patients was (1.02±0.29) mSv/MBq.

RadioimmunotherapyRadiation dosageIodine radioisotopes

References

[1]

Hornick J L, Sharifi J, Khawli L A, et al. Cancer Biother Radiopharm, 1998, 13: 255-268.

[2]

Hornick J L, Sharifi J, Khawli L A, et al. J Nucl Med, 2000, 41: 355-362.

[3]

Hornick J L, Khawli L A, Hu P S, et al. Clin Cancer Res, 1999, 5: 51-60.

[4]

Zhu S P, Li Z. (ed). Radiation toxicology. 2nd. Beijing: Atomic Energy Press (in Chinese), 1992: 73.

[5]

Eary J F, Appelbaum F I, Durack L, et al. Med Phys, 1989, 16: 382-387.

[6]

Breitz H B, Fisher D R, Weiden P L, et al. J Nucl Med, 1993, 34: 908-917.

[7]

Wang J X, Chen R S, Zhu H D, et al. (ed). Anatomy, physical, and metabolic database of Chinese reference man (in Chinese). Beijing: Atomic Energy Press, 1998: 27.

[8]

Koral K F, Zasadny K R, Ackermann R J, et al. Med Phys, 1998, 25: 85-91.

[9]

Nachar O, Rousseau J A, Leflbvre B, et al. J Nucl Med, 1999, 40: 1728-1736.

[10]

Pan Zhongyun (ed). Clinical nuclear medicine (in Chinese). Beijing: Atomic Energy Press, 1994: 88-96.

[11]

Stabin M G. J Nucl Med, 1996, 37: 538-546.

[12]

Buchegger F, Vieira J M, Blaeuenstein P, et al. Eur J Nucl Med, 2003, 30:239-246.

[13]

Koral K F, Zasadny K R, Kessler M L, et al. J Nucl Med, 1994, 35: 1714-1720.

[14]

Xia F N.

Radiation protection

. in Liu CZ (ed), Experimental nuclear medicine and radiopharmaceutical (in Chinese). Beijing: People’s Medical Publishing House, 1999. 48-67.

Baidu Scholar

Google Scholar

[15]

Clifford K S, Carlos C, Luther A P, et al. (ed), Wang SL, Liu YP, Sun Q, et al. (translated). Radiation oncology—Management decisions. Tianjin: Tianjin Science & Technology Translation and Publishing Corp., 2001: 245-259.